SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:
- Jefferies 2019 London Healthcare Conference on Thursday, November 21st at 8:00 a.m. GMT
- Evercore ISI 2nd Annual HealthCONx Conference in Boston on Thursday, December 5th at 2:00 p.m. ET
Both of these presentations will be webcast live and can be accessed by visiting the “Presentations” page of the investor relations section of the company's website here. Replays of the presentations will be archived for a period of 90 days following the conclusion of the live event.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.